The Present Efficacy of Multiple Sclerosis Therapeutics: Is the New 66% Just the Old 33%?

Neurology - United States
doi 10.1212/wnl.0b013e3181b9c8f7
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

The New Era of Multiple Sclerosis Therapeutics

Neurotherapeutics
NeurologyPharmacology
2012English

Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics

Medicinal Chemistry
Drug Discovery
2018English

Optimizing Therapeutics in the Management of Patients With Multiple Sclerosis: A Review of Drug Efficacy, Dosing, and Mechanisms of Action

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2013English

Multiple Sclerosis: Is Clinical Efficacy Sidetracked by Health Economics?

Journal of Economics Theory
2012English

Updated Properties of the Old Open Cluster Melotte 66: Searching for Multiple Stellar Populations

Astronomy and Astrophysics
AstrophysicsAstronomyPlanetary ScienceSpace
2014English

Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights From Functional MRI

Radiology
Nuclear MedicineRadiologyImaging
2018English

Is the Hygiene Hypothesis Relevant for the Risk of Multiple Sclerosis?

Acta Neurologica Scandinavica
MedicineNeurology
2017English

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Novel Therapeutics for Multiple Sclerosis Designed by Parasitic Worms

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy